<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523340</url>
  </required_header>
  <id_info>
    <org_study_id>MENTOR_2011</org_study_id>
    <nct_id>NCT01523340</nct_id>
  </id_info>
  <brief_title>A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response</brief_title>
  <acronym>MENTOR</acronym>
  <official_title>Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Trial design: Prospective observational study

        2. Target population: 200 NSCLC patients with histologically or cytologically confirmed
           stage IV or recurrent NSCLC who have progressive disease after 1st line chemotherapy who
           consent for study participation and meet the study selection criteria

        3. Primary objective: To investigate C-met expression/amplification and EGFR gene mutations
           in NSCLC patients treated with Erlotinib

             -  C-met expression by IHC C-met amplification by SISH EGFR mutation by real time PCR

        4. We will also assess the correlation of EGFR mutations and c-MET with clinical outcome
           (Overall Response Rate, Progression Free survival )

        5. Duration of Trial Recruitment: 2 years
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The rates of C-met expression/amplification and EGFR gene mutations</measure>
    <time_frame>Average of 1 year</time_frame>
    <description>To investigate C-met expression/amplification and EGFR gene mutations in NSCLC patients treated with Erlotinib
: C-met expression by IHC C-met amplification by SISH EGFR mutation by real time PCR</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-small Cell Lung Cancer Metastatic</condition>
  <condition>Non-small Cell Lung Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Erlotinib treatment</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      NSCLC tumor tissue for c-MET expression by immuohistochemistry c-MET amplification by silver
      in situ hybridization EGFR mutation by realtime PCR
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histologically or cytologically confirmed stage IV or recurrent NSCLC who
        have progressive disease after 1st line chemotherapy who consent for study participation
        and meet the study selection criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  19~80 year old male or female

          -  Histologically proven advanced or metastatic NSCLC

          -  Failed to 1st line chemotherapy

          -  Tumor tissue for genetic analysis

          -  Evaluable target lesion by RECIST v1.1

          -  ECOG performance from 0 to 3

          -  Expected survival more than 12 weeks

        Exclusion Criteria:

          -  Previous treatment of EGFR-tyrosine kinase inhibitors

          -  Severe hypersensitivity to erlotinib

          -  Residual toxicities (above grade 2) after previous chemotherapy

          -  Total bilirubin more than 1.5x of upper normal limit Liver function tests more than
             2.5x of upper normal limits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Chul Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Chul Kim, MD, PhD</last_name>
    <phone>+82-61-379-7614</phone>
    <email>kyc0923@chonnam.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>In-Jae Oh, MD, PhD</last_name>
    <phone>+82-61-379-7617</phone>
    <email>droij@chonnam.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Jeonnam</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Chul Kim, MD, PhD</last_name>
      <phone>+82-61-379-7614</phone>
      <email>kyc0923@chonnam.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>In-Jae Oh, MD, PhD</last_name>
      <phone>+82-61-379-7617</phone>
      <email>droij@chonnam.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Young-Chul Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>In-Jae Oh, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoo-Duk Choi, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hee-Jung Ban, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Young-Chul Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

